Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
11 Dezembro 2022 - 12:00PM
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in
developing novel, controllable cellular immunotherapies for
cancers, today announced a poster presentation by the University of
North Carolina Lineberger Comprehensive Cancer Center (UNC
Lineberger) team at the 64th American Society of Hematology (ASH)
Annual Meeting and Exposition being held in New Orleans December
10-13, 2022. The presentation, scheduled for today at 6 p.m. CT,
will provide data on four patients who received rimiducid to
activate the CaspaCIDe® safety switch in an investigator sponsored
trial.
The poster titled “Abrogation of Immune Effector Cell
Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients
Treated with CD19-Specific Chimeric Antigen Receptor Modified
T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9
CAR.19)” will also be available on Bellicum’s website.
The UNC Lineberger research team reported the clinical and
pharmacodynamic courses of ICANS for four patients treated with
rimiducid in an ongoing cell dose expansion cohort of a Phase I/II
trial of iC9 CAR.19 cells to treat B-lymphoblastic leukemia
(B-ALL). According to the poster, rimiducid administration to these
patients experiencing corticosteroid-unresponsive grade 3-4 ICANS
was associated with abrupt reduction of circulating iC9 CAR.19
cells and lower ICANS grade within 24 hours. The UNC Lineberger
research team concluded that iC9 holds promise as a tool to
potentially abrogate the most severe CAR T-cell toxicities.
“There is an unmet need in the management of severe ICANS, and
these results suggest that the iC9 switch may mitigate such
life-threatening toxicities,” commented Natalie Grover, M.D.,
clinical director of UNC Lineberger’s cellular therapy program. “We
look forward to further studies to explore ways to manage adverse
reactions and improve patient outcomes for cellular immunotherapy
regimens.”
“These encouraging findings from UNC reinforce the potential
benefit of the CaspaCIDe safety switch and rimiducid in resolving
CAR T-cell related adverse events,” said Rick Fair, President &
CEO of Bellicum Pharmaceuticals. “We continue to support
further clinical evaluation of the technology and remain committed
to incorporating this important safety feature more broadly in
additional cell therapies.”
The UNC Lineberger team is exploring lower doses of rimiducid to
determine if—by preserving a higher percentage of CAR-T
cells—toxicity may be mitigated without diminishing the therapeutic
benefit.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving
to deliver cures through controllable cell therapies. The company’s
next-generation product candidates are differentiated by powerful
cell signaling technologies designed to produce more effective
CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates,
BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell
products capable of overriding key immune inhibitory mechanisms.
More information about Bellicum can be found
at www.bellicum.com or follow us
on Twitter or LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Bellicum may, in some cases, use
terms such as “continue,” “designed,” “may,” “will,” “potential” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking
statements include statements regarding Bellicum’s intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the applications and benefits of,
as well as additional clinical support for, the CaspaCIDe safety
switch and rimiducid in resolving CAR T-cell related adverse
events, and incorporation of the CaspaCIDe safety switch and
rimiducid into additional cell therapies. Various factors may cause
differences between Bellicum’s expectations and actual results,
including, among others, the impact of the COVID-19 pandemic and
the fludarabine shortage on Bellicum’s clinical trial sites and
trial enrollment, future study results, including those conducted
with larger patient populations, may demonstrate that CaspaCIDe and
rimiducid are not be as effective in resolving adverse events
associated with cell therapies as reported by the UNC Lineberger
research team, interest in CaspaCIDe and rimiducid may not be as
expected, alternative or competitor products and technologies may
be introduced, other factors, such as safety issues, may impact
Bellicum’s clinical progress, actual expenses incurred may be
higher than anticipated, and trial results may be different than
anticipated, as discussed in greater detail under the heading “Risk
Factors” in Bellicum’s filings with the Securities and Exchange
Commission, including without limitation Bellicum’s quarterly
report on Form 10- Q for the three months ended September 30, 2022
and Bellicum’s annual report on Form 10-K for the year ended
December 31, 2021. Any forward-looking statements that Bellicum
makes in this press release speak only as of the date of this press
release. Bellicum assumes no obligation to update Bellicum’s
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Source: Bellicum Pharmaceuticals
Investors:Robert H. UhlManaging DirectorICR
Westwicke858-356-5932Robert.uhl@westwicke.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024